ArticleAtherosclerosis2017
The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study.
Article in Atherosclerosis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Lipoprotein(a) and the Risk of Heart Failure: A Dose-Response Meta-Analysis.Clinical cardiology · 2026Pooled it
- Lipoprotein(a) and heart failure: a systematic review.Heart failure reviews · 2023Pooled it
- Genome-wide association and multi-trait analyses characterize the common genetic architecture of heart failure.Nature communications · 2022Pooled it
- Impact of hypertension on associations of all-cause mortality with admission lipoprotein (a) in acute decompensated heart failure.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Association Between Lipoprotein(a) and Cardiac Remodeling Across Race and Ethnicity in the Multi-Ethnic Study of Atherosclerosis.Circulation. Population health and outcomes · 2026Article
- Lipoprotein(a) Levels and Adverse Outcomes in Heart Failure.Journal of cardiac failure · 2026Article
- Lipoprotein(a): A Novel Risk Factor for Heart Failure and Biomarker of Prognosis? From Pathophysiology to Clinical Practice.Cardiac failure review · 2026Review
- Lipoprotein(a) in Japanese Patients With Cardiovascular Disease: A Systematic Review.JACC. Asia · 2025Review
- Left ventricular myocardial molecular profile of human diabetic ischaemic cardiomyopathy.EMBO molecular medicine · 2025Article
- Lp(a) in daily clinical routine: risk-factor for both cardiovascular events and heart-failure? A retrospective analysis of the Luebeck Lp(a) heart-failure (HF) registry in patients after myocardial infarction.Atherosclerosis plus · 2025Article
- PCSK-9 Inhibitors Can Significantly Improve the Coronary Slow Flow Caused by Elevated Lipoprotein (a) in ST-Elevation Myocardial Infarction Patients With Chronic Kidney Disease.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Article
- Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi-Ethnic Study of Atherosclerosis: The Pooling Project.Journal of the American Heart Association · 2025Article
- Comparing 3 Evidence-Based Strategies to Reduce Cardiovascular Disease Burden: An Individual-Based Cardiometabolic Policy Simulation.Journal of the American Heart Association · 2025Article
- Lipoprotein(a) and panvascular disease.Lipids in health and disease · 2025Review
- The functions of apolipoproteins and lipoproteins in health and disease.Molecular biomedicine · 2024Review
- Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease risk.BMC medical genomics · 2024Article
- Impact of Social Determinants of Health and Lifestyle on Association Between Lipoprotein(a) and Cardiovascular Events.JACC. Advances · 2024Article
- High lipoprotein(a): Actionable strategies for risk assessment and mitigation.American journal of preventive cardiology · 2024Review
- Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.Journal of atherosclerosis and thrombosis · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsLipoprotein(a) [Lp(a)] is a proatherogenic lipoprotein associated with coronary heart disease, ischemic stroke, and more recently aortic stenosis and heart failure (HF). We examined the association of Lp(a) levels with incident HF hospitalization in the Atherosclerosis Risk in Communities (ARIC) study. We also assessed the relationship between Lp(a) levels and arterial stiffness as a potential mechanism for development of HF.
methodsLp(a) was measured in 14,154 ARIC participants without prevalent HF at ARIC visit 1 (1987-1989). The association of Lp(a) quintiles with incident HF hospitalization was assessed using Cox proportional-hazards models. Arterial stiffness parameters were stratified based on Lp(a) quintiles, and p-trend was calculated across ordered groups.
resultsAt a median follow-up of 23.4 years, there were 2605 incident HF hospitalizations. Lp(a) levels were directly associated with incident HF hospitalization in models adjusted for age, race, gender, systolic blood pressure, history of hypertension, diabetes, smoking status, body mass index, heart rate, and high-density lipoprotein cholesterol (quintile 5 vs. quintile 1: hazard ratio [HR] 1.24, 95% confidence interval [CI] 1.09-1.41; p-trend across increasing quintiles <0.01), but not after excluding prevalent and incident myocardial infarction cases (HR 1.07, 95% CI 0.91-1.27; p-trend = 0.70). When adjusted for age, gender, and race, Lp(a) quintiles were not significantly associated with arterial stiffness parameters.
conclusionsIncreased Lp(a) levels were associated with increased risk of incident HF hospitalization. After excluding prevalent and incident myocardial infarction, the association was no longer significant. Lp(a) levels were not associated with arterial stiffness parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.